Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that Dr. Sari Fishman, Vice President of Business Development, will present an update on the Company's ongoing Phase IIa study in pancreatic cancer during partnering meetings at the 2025 BIO International Convention, taking place June 16–19 in Boston, MA (link).
The Phase IIa clinical trial is open-label study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one prior line of therapy. The study is assessing the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson, administered orally at a dose of 25 mg twice daily in continuous 28-day cycles. Approximately 20 evaluable patients are expected to be enrolled.
The trial is led by Prof. Salomon Stemmer, a prominent Oncologist and Key Opinion Leader at the Davidoff Center, Rabin Medical Center, Israel. Namodenoson has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
'We are pleased to report that 50% of the planned patient cohort has already been enrolled and that Namodenoson has demonstrated a favourable safety profile,' stated Prof. Salomon Stemmer. 'There is a critical unmet need for safe and effective treatment options for patients with advanced pancreatic cancer who have exhausted standard therapies. This study gives us the opportunity to advance a novel therapeutic approach for this challenging disease, stated Dr. Sari Fishman, VP of Business Development at Can-Fite.'
Can-Fite looks forward to engaging with potential partners and collaborators at BIO 2025 as it continues to progress its clinical pipeline.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
[email protected]
+972-3-9241114
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
Kraft Heinz will remove all artificial dyes from its food
Kraft Heinz, manufacturer of beloved food and drink products from the classic Kraft Mac and Cheese and Heinz ketchup to Kool-Aid and Jell-O, will eliminate the use of all artificial dyes in its products by the end of 2027, the company announced Tuesday. In a June 17 press release, the company said "nearly" 90% of its products were already free of Food, Drug & Cosmetic (FD&C) colors, also known as artificial or synthetic food dyes, and that it would be removing them from the remaining 10% of its products. The manufacturer also said it would not launch any new products using the dyes, effective immediately. The FD&C dyes in question have been and still are allowed for use in food and drink products under U.S. Food and Drug Administration (FDA) guidelines. However, an announcement from Health Secretary Robert F. Kennedy Jr in April indicated the agency is looking to revoke the approval of at least eight "petroleum-based synthetic dyes" in favor of "natural alternatives." Before the end of 2027, Kraft Heinz intends to replace the dyes with natural alternatives or "reinvent" new colors and shades for products where natural replacement color matches are not available. "As a food company with a 150+ year heritage, we are continuously evolving our recipes, products, and portfolio to deliver superiority to consumers and customers,' Pedro Navio, North America President at Kraft Heinz, said in a statement. 'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio." Need a break? Play the USA TODAY Daily Crossword Puzzle. Kennedy praised the move on a June 17 post to X, formerly Twitter, saying this "voluntary step" will phase out "harmful dyes" in brands like Kool-Aid, Jell-O and Crystal Light. Are food dyes getting banned in the US?: What know to about 8 dyes being phased out Is the US banning artificial food dyes? The FDA announced on April 22 that it will "phase out all petroleum-based synthetic dyes from the nation's food supply" by the end of 2026. The dyes have previously been allowed under FDA regulations and oversight. The targeted additives include Red Dye 40, Yellow Dye 5, Yellow Dye 6, Blue Dye 1, Blue Dye 2, Green Dye 3, Citrus Red 2 and Orange B. No formal agreement or legislation was passed officially banning the substances. Instead, HHS and the FDA have a "mutual understanding" with the food industry that the dyes will be progressively removed, Kennedy said at the time. During an April 22 press conference, FDA Commissioner Marty Makary said the agency intends to revoke the approval of some dyes for use and work with industry leaders to substitute petrochemical dyes with "natural" ones. A press statement released by the FDA also said it plans to establish a "national standard and timeline for the transition from petrochemical-based dyes to natural alternatives." The FDA will authorize four new natural color additives and expedite the approval of more, according to its statement. The agency will also partner with the National Institutes of Health to research the effect food additives have on children's health and development. Other companies promise to eliminate artificial dyes Several major food and beverage companies have recently announced their plans to remove ingredients in the wake of the April HHS announcement. At an April 24 earnings call, PepsiCo CEO Ramon Laguarta said the company's transition away from artificial colors was underway, with more than 60 percent of its business already in compliance. Popular snack brands under its portfolio like Lays, Doritos and Tostitos, will stop using artificial colors by the end of the year under the directive. Tyson Foods made a similar promise in May, telling Reuters it was "proactively reformulating" products to eliminate the use of petroleum-based synthetic dyes by the end of the month. Mars, Inc., the producer of Skittles, also announced in late May that it would be removing titanium dioxide from the colorful candy.
Yahoo
an hour ago
- Yahoo
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors. The voting results, resolution by resolution, are available in the Investors & Media section of the Company's website (Shareholders Meeting | GENFIT). ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, G1090N, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, such as "believe", "potential", "expect", 'target', 'may', 'will', "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website ( and the AMF's website ( and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | InvestorsTel: +33 3 2016 4000 | investors@ PRESS RELATIONS | MediaStephanie Boyer – Press relations | Tel: +333 2016 4000 | GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT June 17, 2025 Combined Shareholders Meeting ResultsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
4 hours ago
Kraft Heinz to remove artificial dyes from food products over next 2 years
Kraft Heinz announced on Tuesday that it would be removing artificial food dyes from its products within the next two years. The company said 10% of its products currently contain FD&C color additives, which are approved for use in food by the U.S. Food and Drug Administration (FDA), including brands such as Crystal Light, Jell-O and Kool Aid. Pedro Navio, North America president at Kraft Heinz, said in a statement that the company removed artificial colors, preservatives and flavors from its Kraft macaroni and cheese in 2016 and that its Heinz tomato ketchup has never had artificial dyes. "As a food company with a 150+ year heritage, we are continuously evolving our recipes, products, and portfolio to deliver superiority to consumers and customers," Navio's statement read, in part. "The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio. … Above all, we are focused on providing nutritious, affordable, and great-tasting food for Americans and this is a privilege we don't take lightly." It comes after Health and Human Services Secretary Robert F. Kennedy Jr. unveiled a plan in April to start phasing out eight synthetic food dyes in the American food supply. At a news conference announcing the plan, FDA Commissioner Dr. Marty Makary said health agencies were looking to revoke authorization for two synthetic food colorings and to work with the food industry to eliminate six remaining synthetic dyes used in a variety of food products. Kennedy said the agencies had reached an "understanding" with major food companies to voluntarily remove artificial food dyes from their products. It's unclear what action Kennedy could take if the companies don't comply. Shortly after Kennedy's announcement, PepsiCo's CEO said on an earnings call that the company had already begun phasing out artificial colors. In-N-Out also announced in May it was removing artificial food dyes from menu items. Other companies, like Kellogg's, have previously stated their products are safe for consumption, and they are following federal standards set by the FDA. Last month, the FDA approved two dyes and expanded approval of a third, meaning it can now be used in a wider range of food products. Some studies have linked dyes to behavioral changes in children as well as to cancer in animals, suggesting this could extend to humans. Some nutritionists and dietitians say that it's best to avoid artificial food dyes, while others say more research needs to be done and the potential negative effects are still unclear.
